April 2, 2020 /
Mark Johnson / Milwaukee Journal Sentinel
A potential vaccine for COVID-19 has been developed and tested successfully in mice, researchers reported Thursday. 
“We’d like to get this into patients as soon as possible,” said Andrea Gambotto, associate professor of surgery at the University of Pittsburgh School of Medicine and co-author of a paper announcing the vaccine in the journal EBioMedicine.
As far as reaching clinical trials, “we would like to think a month, give or take. Maybe two months. We just started the process,” said co-author Louis Falo, a professor and chairman of the Department of Dermatology at the University of Pittsburgh.
Thursday’s announcement, more than three months into a pandemic that has killed 50,000 people and sickened almost 1 million worldwide, presents an urgent challenge to government regulators, who must weigh how much to speed up the vaccine approval process.
Vaccines often take years to receive approval from the U.S. Food and Drug Administration. Yet on March 16, the first four healthy volunteers in Seattle received a different potential COVID-19 vaccine, made by a company called Moderna and administered in a small clinical trial at Kaiser Permanente Washington Health Research Institute.